The prevalence of allergic rhinitis is approximately 10% to 40% in the West. It is estimated that my country is also close to 10%, and the trend of rising year by year. The World Health Organization believes that "global respiratory allergic disease epidemic is growing." Recently, Sino-US Tianjin Shike Pharmaceutical Co., Ltd. officially pushed Berkner in China's continental drug market in China's allergic rhinitis.
Burkener (propionate chlorine spray) is developed by the mother of Sino-US Hike's mother, Glaxo Take Company, entered the non-prescribed drug catalog in July 2003, which is now responsible for China-US Sike known as the non-prescription drug.
If you do not treat allergic rhinitis in time, you will cause sinusitis, otitis media, nasal polyps, bronchial asthma. Moreover, almost all patients with allergic rhinitis have conjunctivitis. There are also one-third of patients with allergic rhinitis with asthma performance, and two-thirds of patients with asthma have two-thirds of pneumatic inflammation. Patients with allergic rhinitis in asthma patients have 70% to 80%.
The nasal intracle-steroid spray has been recommended by WHO to the preferred medication for the treatment of allergic rhinitis by WHO in 2001. Burkener is a typical representative of nasal intake steroid spray. The mechanism of action of Burkner is for the root cause of allergic rhinitis - the immunosuppression and anti-inflammatory effects of drugs, multi-link, multi-horizontal blocking, and thus effectively relieve nose Nasal symptoms such as sneeze, runny nose, and have a certain preventive role in allergic rhinitis. (Excerpted from Beijing Evening News)
